Alessia Zanelli is a successful entrepreneur and investor in the life sciences sector. Dr. Zanelli began her career in 2000 as Commercial Director of the Italian company Comecer, specialized in the design, engineering, manufacturing and support of advanced containment and aseptic processing systems for the pharmaceutical and nuclear medicine industries. Dr. Zanelli was promoted to General Manager in 2007 and Chief Executive Officer in 2011. She created an “exit” opportunity for the company’s shareholders by initiating and leading M&A negotiations with the Canadian ATS Group (advanced automation systems), which ultimately acquired Comecer in 2019. Since then, Dr. Zanelli has served as a Board member and investor, either directly or as a club deal member, in companies such as Tensive, Cellply (advanced analytical tools for in-depth characterization of cancer immunotherapies, cell therapies and cell biotherapies), Medendi (precision healthcare for cancer, through advanced molecular diagnostics, such as genomic and proteomic analyses, and personalized therapeutic guidance based on tumor molecular profiling) and Cristallina Holding S.p.A. (mineral waters).